Lundbeck's Northera Now Available Through Specialty Pharmacy

New treatment option for treatment of orthostatic dizziness.

It has been a long road to get Northera (droxidopa) to its patients but the wait is over. Today, Lundbeck announced Northera capsules are now available for healthcare providers to prescribe in the United States.

Northera is a norepinephrine prodrug that was recently approved for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

In a press release, Staffan Schüberg, president of Lundbeck in the U.S. said “For people living with symptomatic NOH, the availability of Northera may provide a new treatment option to discuss with their healthcare provider,” adding “As a company with a long-standing and proven track record of working closely with smaller patient populations facing considerable unmet medical needs, we are passionate about delivering this needed therapy to patients and their families.”

Judy Biedenharn, president of the Multiple System Atrophy (MSA) Coalition added, “Our entire community of patients rallied to help ensure Northera gained FDA approval, and we’re delighted that it’s now available throughout the US.”

Click here to read the full article on Rare Disease Report.